Vaccination Ameliorates Cellular Inflammatory Responses in SARS-CoV-2 Breakthrough Infections

Area of Science:

• Immunology
• Virology
• Vaccinology

Background:

• Limited data exist on cellular immune responses in vaccinated individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infections.
• Evaluating these responses can clarify how vaccines mitigate harmful inflammatory reactions.

Purpose of the Study:

• To investigate peripheral blood cellular immune responses in vaccinated patients experiencing SARS-CoV-2 breakthrough infections.
• To compare these responses with those in unvaccinated individuals with varying disease severity.

Main Methods:

• A prospective study was conducted on 118 participants with SARS-CoV-2 infection.
• Peripheral blood samples were analyzed for cellular immune markers in 21 vaccinated and 97 unvaccinated patients stratified by disease severity.

Main Results:

• Vaccinated patients with breakthrough infections showed higher percentages of antigen-presenting monocytes, mature monocytes, functional T cells, and mature neutrophils.
• Conversely, vaccinated individuals had lower percentages of activated T cells, activated neutrophils, and immature B cells compared to unvaccinated patients.
• These immune differences were more pronounced with increased disease severity in unvaccinated individuals, with cellular activation persisting for up to 8 months in unvaccinated mild cases.

Conclusions:

• SARS-CoV-2 breakthrough infections in vaccinated individuals elicit cellular immune responses that curb inflammatory progression.
• These responses indicate potential mechanisms by which vaccines reduce disease severity.
• The findings may inform the development of more effective vaccines and therapies against SARS-CoV-2.